Nama's AI scorecard currently rates Bruker Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is BRKR's P/E ratio?

Bruker trades at a trailing price-to-earnings ratio of 31.4.

When does BRKR report earnings?

Bruker's next scheduled report is on Feb 11, 2027. Analysts expect EPS of $0.80.

What is the BRKR price target?

The median analyst price target from 12 analysts is $64.50, with a range of $50.00 – $80.00.

Is BRKR Shariah compliant?

Nama's AAOIFI-style screen reads Bruker as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Does BRKR pay a dividend?

Yes — Bruker's dividend yield is 0.3%.

Nama Insights

Bruker (BRKR)

Healthcare · Medical Devices · NASDAQ

Bruker (BRKR) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $9.34B, a trailing price-to-earnings ratio of 31.4 and a free-cash-flow yield of 0.1%. Over the most recent reported fiscal year, revenue grew 2.1% and free cash flow per share fell 89.9%. Nama's AI scorecard rates it Hold, 4.5 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Hold · 4.5/10

The sections balance. As of Nov 7, 2026.

Momentum

Rising · +51.9% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-35.4%

How far the last close sits under the highest price of the past five years.

Market cap	$9.34B
Trailing P/E	31.4
Price / book	3.9
Price / sales	2.7
FCF yield	0.1%
Dividend yield	0.3%
Gross margin	46.4%
Operating margin	7.6%
Net margin	-2.0%
Revenue growth (YoY)	+2.1%
Revenue growth (3-yr annual)	+10.7%
EPS growth (YoY)	-24.1%
FCF/share growth (YoY)	-89.9%
Beta	1.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Devices

BRKR earnings

Next report: Feb 11, 2027 (Q4 2026, EPS estimate $0.80). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$0.56	$0.42	+33.3%	—
Q2 2026	Aug 4, 2026	$0.49	$0.38	+28.9%	$838.50M
Q1 2026	May 6, 2026	$0.31	$0.23	+34.8%	$823.40M
Q4 2025	Feb 12, 2026	$0.59	$0.65	-9.2%	$977.20M

BRKR analyst price target

Median target $64.50 from 12 analysts, ranging $50.00 – $80.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live BRKR data on Nama Insights →

Recent Congressional trades

Bruker trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Thomas R Carper	Senate	Buy	$1,001 - $15,000	—

BRKR FAQ

Is BRKR a buy?: Nama's AI scorecard currently rates Bruker Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is BRKR's P/E ratio?: Bruker trades at a trailing price-to-earnings ratio of 31.4.
When does BRKR report earnings?: Bruker's next scheduled report is on Feb 11, 2027. Analysts expect EPS of $0.80.
What is the BRKR price target?: The median analyst price target from 12 analysts is $64.50, with a range of $50.00 – $80.00.
Is BRKR Shariah compliant?: Nama's AAOIFI-style screen reads Bruker as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does BRKR pay a dividend?: Yes — Bruker's dividend yield is 0.3%.